Literature DB >> 16282341

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Carolina Berger1, Mary E Flowers, Edus H Warren, Stanley R Riddell.   

Abstract

The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft versus host disease. However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination. We show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CD8+ and CD4+ T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells. Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and quantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes. Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells. These studies demonstrate the need for nonimmunogenic suicide genes and identify a strategy for detection of CD4+ and CD8+ T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials. The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282341      PMCID: PMC1895724          DOI: 10.1182/blood-2005-08-3503

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.

Authors:  E Goulmy
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

2.  Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.

Authors:  C S Higano; D Chielens; W Raskind; E Bryant; M E Flowers; J Radich; R Clift; F Appelbaum
Journal:  Blood       Date:  1997-10-01       Impact factor: 22.113

3.  A novel murine retrovirus identified during testing for helper virus in human gene transfer trials.

Authors:  A D Miller; L Bonham; J Alfano; H P Kiem; T Reynolds; G Wolgamot
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

4.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

5.  X-linked IAP is a direct inhibitor of cell-death proteases.

Authors:  Q L Deveraux; R Takahashi; G S Salvesen; J C Reed
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

6.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

7.  Production and culture of HSVtk transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition.

Authors:  F C Marini; S M Kornblau
Journal:  Bone Marrow Transplant       Date:  1999-05       Impact factor: 5.483

8.  Synthetic activation of caspases: artificial death switches.

Authors:  R A MacCorkle; K W Freeman; D M Spencer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

10.  Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors.

Authors:  S Verzeletti; C Bonini; S Marktel; N Nobili; F Ciceri; C Traversari; C Bordignon
Journal:  Hum Gene Ther       Date:  1998-10-10       Impact factor: 5.695

View more
  151 in total

1.  Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.

Authors:  Dean O Campbell; Shahriar S Yaghoubi; Ying Su; Jason T Lee; Martin S Auerbach; Harvey Herschman; Nagichettiar Satyamurthy; Johannes Czernin; Arnon Lavie; Caius G Radu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

Review 2.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 3.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

4.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 5.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

6.  A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells.

Authors:  C Berger; M Berger; D Anderson; S R Riddell
Journal:  J Med Primatol       Date:  2010-11-02       Impact factor: 0.667

Review 7.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Authors:  Xiuli Wang; Araceli Naranjo; Christine E Brown; Cherrilyn Bautista; Chinglam W Wong; Wen-Chung Chang; Brenda Aguilar; Julie R Ostberg; Stanley R Riddell; Stephen J Forman; Michael C Jensen
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

9.  Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Authors:  Usanarat Anurathapan; Robert C Chan; Hakeem F Hindi; Roopa Mucharla; Pradip Bajgain; Brendan C Hayes; William E Fisher; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Mol Ther       Date:  2013-11-28       Impact factor: 11.454

10.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.